Search results
Results from the WOW.Com Content Network
For each category, patients were rated on a 5-point scale: 0 is normal, 0.5 is questionable dementia and 1, 2 and 3 are mild, moderate and severe stages of dementia, respectively.
An Alzheimer’s disease drug may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Under the proposed changes, the medication ...
With full FDA approval for the groundbreaking Alzheimer’s drug Leqembi, Medicare coverage takes a big step forward into a new era of treatment.
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [6] [7] It was developed by Biogen and Eisai ...
Safety risks and accessibility of new Alzheimer’s drugs. The modest clinical benefits conferred by anti-amyloid antibody treatments need to be weighed against the risks, costs, and accessibility ...
Blarcamesine (developmental code name ANAVEX 2-73) is an experimental drug which is under development for the treatment of Alzheimer's disease and a variety of other indications. [ 1 ] Blarcamesine acts as an agonist of the sigma σ 1 receptor , the muscarinic acetylcholine M 1 receptor , and the ionotropic glutamate NMDA receptor .
[9] [10] The final conclusion was that "verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer’s disease and was associated with treatment-related adverse events". Verubecestat was projected to be a breakthrough medicine for dementia related illness, however it is still unknown why the medicine ...
The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating ...